Skip to content

Study · Animal study (in vivo) · monkey and rat · 2019

17 results

Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism.

Holten-Andersen L, Pihl S, Rasmussen CE, Zettler J, Maitro G, Baron J, Heinig S, Hoffmann E, Wegge T, Krusch M, Faltinger F, Killian S and 4 more

Show all authors

Sprogoe K, Karpf DB, Breinholt VM, Cleemann F

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research9 Oct 2019Cited by 40 (Europe PMC)

PMID31291476 (opens in a new tab)DOI10.1002/jbmr.3824 (opens in a new tab)PepBankPUB-31291476
Source linkPubMedAsk about this study
Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, TransCon PTH had a half-life of 28 hours.

    In plain wordsIn rats, TransCon PTH had a half-life of 28 hours.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableHalf-life
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Measurements

    Half-life
    28 hours
    rats

    Source sentences

    Summary
    TransCon PTH demonstrated a half-life of 28 and 34 hours in rats and monkeys, respectively.
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In monkeys, TransCon PTH had a half-life of 34 hours.

    In plain wordsIn monkeys, TransCon PTH had a half-life of 34 hours.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableHalf-life
    Study

    monkeyn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (monkey).

    Measurements

    Half-life
    34 hours
    monkeys

    Source sentences

    Summary
    TransCon PTH demonstrated a half-life of 28 and 34 hours in rats and monkeys, respectively.
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, repeated TransCon PTH dosing produced an infusion-like released-PTH profile with low peak-to-trough levels.

    In plain wordsIn rats, repeated TransCon PTH dosing produced an infusion-like PTH profile with low peak-to-trough levels.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableRepeated-dose exposure profile
    Study

    ratn: not reported in source

    Rats
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    After repeated dosing, an infusion-like profile of the released PTH, characterized by low peak-to-trough levels, was obtained in both species.
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In monkeys, repeated TransCon PTH dosing produced an infusion-like released-PTH profile with low peak-to-trough levels.

    In plain wordsIn monkeys, repeated TransCon PTH dosing produced an infusion-like PTH profile with low peak-to-trough levels.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableRepeated-dose exposure profile
    Study

    monkeyn: not reported in source

    Monkeys
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (monkey).

    Source sentences

    Summary
    After repeated dosing, an infusion-like profile of the released PTH, characterized by low peak-to-trough levels, was obtained in both species.
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In intact rats, daily subcutaneous TransCon PTH was associated with increased serum calcium.

    In plain wordsIn rats, daily subcutaneous TransCon PTH was linked to increased serum calcium.

    Peptide
    Palopegteriparatide
    Outcome
    IncreaseSerum calcium
    Study

    ratn: not reported in source

    Intact rats
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    In intact rats and monkeys, daily subcutaneous administration of TransCon PTH was associated with increases in serum calcium (sCa) levels and decreases in serum phosphate levels (sP).
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In intact monkeys, daily subcutaneous TransCon PTH was associated with increased serum calcium.

    In plain wordsIn monkeys, daily subcutaneous TransCon PTH was linked to increased serum calcium.

    Peptide
    Palopegteriparatide
    Outcome
    IncreaseSerum calcium
    Study

    monkeyn: not reported in source

    Intact monkeys
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (monkey).

    Source sentences

    Summary
    In intact rats and monkeys, daily subcutaneous administration of TransCon PTH was associated with increases in serum calcium (sCa) levels and decreases in serum phosphate levels (sP).
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In intact rats, daily subcutaneous TransCon PTH was associated with decreased serum phosphate.

    In plain wordsIn rats, daily subcutaneous TransCon PTH was linked to decreased serum phosphate.

    Peptide
    Palopegteriparatide
    Outcome
    DecreaseSerum phosphate
    Study

    ratn: not reported in source

    Intact rats
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    In intact rats and monkeys, daily subcutaneous administration of TransCon PTH was associated with increases in serum calcium (sCa) levels and decreases in serum phosphate levels (sP).
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In intact monkeys, daily subcutaneous TransCon PTH was associated with decreased serum phosphate.

    In plain wordsIn monkeys, daily subcutaneous TransCon PTH was linked to decreased serum phosphate.

    Peptide
    Palopegteriparatide
    Outcome
    DecreaseSerum phosphate
    Study

    monkeyn: not reported in source

    Intact monkeys
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (monkey).

    Source sentences

    Summary
    In intact rats and monkeys, daily subcutaneous administration of TransCon PTH was associated with increases in serum calcium (sCa) levels and decreases in serum phosphate levels (sP).
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In monkeys, a single TransCon PTH dose that increased serum calcium within normal limits concurrently decreased urinary calcium excretion.

    In plain wordsIn monkeys, a single TransCon PTH dose increased serum calcium within normal limits and concurrently decreased urinary calcium excretion.

    Peptide
    Palopegteriparatide
    Outcome
    DecreaseUrinary calcium after a single dose
    Study

    monkeyn: not reported in source

    Monkeys
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · subcutaneousAs given in this study (monkey).

    Source sentences

    Summary
    In monkeys, at a single dose of TransCon PTH that increased sCa levels within the normal range, a concurrent decrease in uCa excretion was observed.
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In intact rats, urinary calcium excretion with repeated TransCon PTH dosing was comparable to controls across all doses despite serum calcium increases.

    In plain wordsIn rats, urinary calcium excretion with repeated TransCon PTH dosing was comparable to controls despite serum calcium increases.

    Peptide
    Palopegteriparatide
    Outcome
    No significant changeUrinary calcium after repeat dosing
    Study

    ratn: not reported in source

    Intact rats
    Comparator
    Controls
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    In 4-week repeat-dose studies in intact rats and monkeys, uCa excretion was comparable to controls across all dose levels despite increases in sCa levels.
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In intact monkeys, urinary calcium excretion with repeated TransCon PTH dosing was comparable to controls across all doses despite serum calcium increases.

    In plain wordsIn monkeys, urinary calcium excretion with repeated TransCon PTH dosing was comparable to controls despite serum calcium increases.

    Peptide
    Palopegteriparatide
    Outcome
    No significant changeUrinary calcium after repeat dosing
    Study

    monkeyn: not reported in source

    Intact monkeys
    Comparator
    Controls
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · subcutaneous · 4 weeksAs given in this study (monkey).

    Source sentences

    Summary
    In 4-week repeat-dose studies in intact rats and monkeys, uCa excretion was comparable to controls across all dose levels despite increases in sCa levels.
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In hypoparathyroid rats, TransCon PTH normalized serum calcium throughout the day versus only transient normalization trends with higher-dose PTH(1-84).

    In plain wordsIn rats with hypoparathyroidism, TransCon PTH normalized serum calcium throughout the day versus transient normalization trends with higher-dose PTH(1-84).

    Peptide
    Palopegteriparatide
    Outcome
    Direction not reportedSerum calcium normalization
    Study

    ratn: not reported in source

    Hypoparathyroidism
    Comparator
    PTH(1-84) at up to sixfold higher molar dose
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Further, in a rat model of HP, TransCon PTH normalized sCa and sP levels 24 hours per day. This was in contrast to only transient trends toward normalization of sCa and sP levels with an up to 6-fold higher molar dose of PTH(1-84).
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In hypoparathyroid rats, TransCon PTH normalized serum phosphate throughout the day versus only transient normalization trends with higher-dose PTH(1-84).

    In plain wordsIn rats with hypoparathyroidism, TransCon PTH normalized serum phosphate throughout the day versus transient normalization trends with higher-dose PTH(1-84).

    Peptide
    Palopegteriparatide
    Outcome
    Direction not reportedSerum phosphate normalization
    Study

    ratn: not reported in source

    Hypoparathyroidism
    Comparator
    PTH(1-84) at up to sixfold higher molar dose
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Further, in a rat model of HP, TransCon PTH normalized sCa and sP levels 24 hours per day. This was in contrast to only transient trends toward normalization of sCa and sP levels with an up to 6-fold higher molar dose of PTH(1-84).
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In hypoparathyroid rats receiving repeated TransCon PTH, urinary calcium transiently increased alongside serum calcium above normal.

    In plain wordsIn rats with hypoparathyroidism receiving repeated TransCon PTH, urinary calcium temporarily increased alongside serum calcium above normal.

    Peptide
    Palopegteriparatide
    Outcome
    IncreaseTransient urinary calcium increase
    Study

    ratn: not reported in source

    Hypoparathyroidism
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    After repeated dosing to HP rats, uCa excretion transiently increased, corresponding to increases in sCa above normal range, but at the end of the treatment period, uCa excretion was generally comparable to sham controls.
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In hypoparathyroid rats receiving repeated TransCon PTH, end-treatment urinary calcium excretion was generally comparable to sham controls.

    In plain wordsIn rats with hypoparathyroidism receiving repeated TransCon PTH, end-treatment urinary calcium excretion was generally comparable to sham controls.

    Peptide
    Palopegteriparatide
    Outcome
    No significant changeEnd-treatment urinary calcium
    Study

    ratn: not reported in source

    Hypoparathyroidism
    Comparator
    Sham controls
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    After repeated dosing to HP rats, uCa excretion transiently increased, corresponding to increases in sCa above normal range, but at the end of the treatment period, uCa excretion was generally comparable to sham controls.
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  16. 16AnimalAnimal study (in vivo)Safety outcome

    In rats and monkeys, TransCon PTH was well tolerated.

    In plain wordsIn rats and monkeys, TransCon PTH was well tolerated.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableTolerability
    Study

    rats and monkeysn: not reported in source

    Preclinical dosing studies
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rats and monkeys).

    Source sentences

    Summary
    TransCon PTH was well tolerated
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.
  17. 17AnimalAnimal study (in vivo)Efficacy outcome

    In monkeys, a single TransCon PTH dose increased serum calcium within the normal range.

    In plain wordsIn monkeys, a single TransCon PTH dose increased serum calcium within the normal range.

    Peptide
    Palopegteriparatide
    Outcome
    IncreaseSerum calcium after a single dose
    Study

    monkeyn: not reported in source

    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (monkey).

    Source sentences

    Summary
    In monkeys, at a single dose of TransCon PTH that increased sCa levels within the normal range, a concurrent decrease in uCa excretion was observed.
    1 context sentence
    Summary · context
    To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.